Review

Iron oxide nanoparticle targeting mechanism and its application in tumor magnetic resonance imaging and therapy

Li Wu

Chunting Wang‡

Yu Li‡

Li Wu

*Author for correspondence:

E-mail Address: fdwl525@163.com

https://orcid.org/0000-0001-9200-9376

College of Medical Imaging, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China

Department of Radiology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, 519000, China

Search for more papers by this author

Chunting Wang‡

College of Medical Imaging, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China

‡Chunting Wang and Yu Li contributed equally to this work.

Search for more papers by this author

Yu Li‡

College of Medical Imaging, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China

‡Chunting Wang and Yu Li contributed equally to this work.

Search for more papers by this author

Published Online:2 Dec 2022https://doi.org/10.2217/nnm-2022-0246

View article

Abstract

Iron oxide nanoparticles (IONPs) can be applied to targeted drug delivery, targeted diagnosis and treatment of tumors due to their easy preparation, good biocompatibility, low biotoxicity, high imaging quality, high magnetothermal sensitivity and stable targeting after certain surface modifications. However, the complexity of the mechanism of action and their properties has led to there being few clinical applications of IONPs. This review first describes the targeting mechanisms of IONPs and their toxicity issues, then discusses the applications of IONP targeting studies in tumor MRI. Finally, the applications of IONP targeting in tumor therapy are listed. The authors show the advantages of targeting IONPs and hope that the review will increase the possibility of converting IONPs from biomedical applications to clinical applications.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021).
MedlineGoogle Scholar
2. Xie M, Zhu Y, Xu S et al. A nanoplatform with tumor-targeted aggregation and drug-specific release characteristics for photodynamic/photothermal combined antitumor therapy under near-infrared laser irradiation. Nanoscale 12(21), 11497–11509 (2020).
Medline CASGoogle Scholar
3. Lin Y, Zhang K, Zhang R et al. Magnetic nanoparticles applied in targeted therapy and magnetic resonance imaging: crucial preparation parameters, indispensable pre-treatments, updated research advancements and future perspectives. J. Mater. Chem. B 8(28), 5973–5991 (2020). •• Summarizes the main biomedical applications of magnetic nanoparticles and provides a clear understanding of the current research progress of iron oxide nanoparticles (IONPs) and the direction of further research.
Medline CASGoogle Scholar
4. Zhao S, Yu X, Qian Y, Chen W, Shen J. Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics. Theranostics 10(14), 6278–6309 (2020).
Medline CASGoogle Scholar
5. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148(2), 135–146 (2010).
Medline CASGoogle Scholar
6. Nagy JA, Vasile E, Feng D et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196(11), 1497–1506 (2002).
Medline CASGoogle Scholar
7. Omidi Y, Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts 4(2), 55–67 (2014).
MedlineGoogle Scholar
8. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58–62 (2005).
Medline CASGoogle Scholar
9. Huang D, Sun L, Huang L, Chen Y. Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. J. Pers. Med. 11(2), 124 (2021). • Discusses abnormal angiogenesis, abnormal vascular structure, irregular blood flow, extensive permeability of tumor vessels and the enhanced permeability and retention effect from the perspective of tumor vessels and proposes that the enhanced permeability and retention effect could be increased by nanoparticles modulating tumor vessels.
MedlineGoogle Scholar
10. Alphandéry E. Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease. Nanotoxicology 13(5), 573–596 (2019).
Medline CASGoogle Scholar
11. Wang D, Fei B, Halig LV et al. Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano 8(7), 6620–6632 (2014).
Medline CASGoogle Scholar
12. Dhas N, Kudarha R, Pandey A et al. Stimuli responsive and receptor targeted iron oxide based nanoplatforms for multimodal therapy and imaging of cancer: conjugation chemistry and alternative therapeutic strategies. J. Control. Release 333, 188–245 (2021). •• Introduces and describes the particular concept of stimuli-responsiveness, including endogenous, exogenous and dual-/multi-stimulus-based delivery platforms.
Medline CASGoogle Scholar
13. Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. Curr. Pharm. Des. 19(35), 6315–6329 (2013).
Medline CASGoogle Scholar
14. Hadjipanayis CG, Machaidze R, Kaluzova M et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70(15), 6303–6312 (2010).
Medline CASGoogle Scholar
15. Farran B, Montenegro RC, Kasa P et al. Folate-conjugated nanovehicles: strategies for cancer therapy. Mater. Sci. Eng. C. Mater. Biol. Appl. 107, 110341 (2020).
Medline CASGoogle Scholar
16. Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 9, 2539–2555 (2014).
MedlineGoogle Scholar
17. Lima-Tenório MK, Pineda EA, Ahmad NM, Fessi H, Elaissari A. Magnetic nanoparticles: in vivo cancer diagnosis and therapy. Int. J. Pharm. 493(1–2), 313–327 (2015).
Medline CASGoogle Scholar
18. Al-Jamal KT, Bai J, Wang JT et al. Magnetic drug targeting: preclinical in vivo studies, mathematical modeling, and extrapolation to humans. Nano Lett. 16(9), 5652–5660 (2016).
Medline CASGoogle Scholar
19. Cole AJ, David AE, Wang J, Galbán CJ, Hill HL, Yang VC. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials 32(8), 2183–2193 (2011).
Medline CASGoogle Scholar
20. Lee N, Yoo D, Ling D, Cho MH, Hyeon T, Cheon J. Iron oxide based nanoparticles for multimodal imaging and magnetoresponsive therapy. Chem. Rev. 115(19), 10637–10689 (2015).
Medline CASGoogle Scholar
21. Latunde-Dada GO. Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim. Biophys. Acta Gen. Subj. 1861(8), 1893–1900 (2017).
Medline CASGoogle Scholar
22. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y. The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases. Oxid. Med. Cell Longev. 2016, 2795090 (2016).
MedlineGoogle Scholar
23. Low LE, Lim HP, Ong YS et al. Stimuli-controllable iron oxide nanoparticle assemblies: Design, manipulation and bio-applications. J. Control. Release 345, 231–274 (2022).
Medline CASGoogle Scholar
24. Aboushoushah S, Alshammari W, Darwesh R, Elbaily N. Toxicity and biodistribution assessment of curcumin-coated iron oxide nanoparticles: multidose administration. Life Sci. 277, 119625 (2021).
Medline CASGoogle Scholar
25. Huang X, Lin C, Luo C et al. Fe(₃)O(₄)@M nanoparticles for MRI-targeted detection in the early lesions of atherosclerosis. Nanomedicine-UK 33, 102348 (2021).
Medline CASGoogle Scholar
26. Huang Y, Hsu JC, Koo H, Cormode DP. Repurposing ferumoxytol: diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics 12(2), 796–816 (2022).
Medline CASGoogle Scholar
27. Avasthi A, Caro C, Pozo-Torres E, Leal MP, García-Martín ML. Magnetic nanoparticles as MRI contrast agents. Top. Curr. Chem. 378(3), 40 (2020). •• Summarizes in vivo studies of IONPs in animal models, with special emphasis on tumor model-related studies, and clearly compares untargeted and targeted IONPs and describes the advantages of targeting IONPs and current research progress.
CASGoogle Scholar
28. Geraldes CFGC, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol. Imaging 4(1), 1–23 (2009).
Medline CASGoogle Scholar
29. Peng Y, Tsang SCE, Chou P. Chemical design of nanoprobes for T1-weighted magnetic resonance imaging. Mater. Today 19(6), 336–348 (2016).
CASGoogle Scholar
30. Chiarelli PA, Revia RA, Stephen ZR et al. Nanoparticle biokinetics in mice and nonhuman primates. ACS Nano 11(9), 9514–9524 (2017).
Medline CASGoogle Scholar
31. Xie W, Guo Z, Gao F et al. Shape-, size- and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic theranostics. Theranostics 8(12), 3284–3307 (2018).
Medline CASGoogle Scholar
32. Koikkalainen J, Rhodius-Meester H, Tolonen A et al. Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clin. 11, 435–449 (2016).
MedlineGoogle Scholar
33. Currie S, Hoggard N, Craven IJ, Hadjivassiliou M, Wilkinson ID. Understanding MRI: basic MR physics for physicians. Postgrad. Med. J. 89(1050), 209–223 (2013).
MedlineGoogle Scholar
34. Jeon M, Halbert MV, Stephen ZR, Zhang M. Iron oxide nanoparticles as T1 contrast agents for magnetic resonance imaging: fundamentals, challenges, applications, and prospectives. Adv. Mater. 33(23), 1906539 (2021).
CASGoogle Scholar
35. Wang J, Huang Y, David AE et al. Magnetic nanoparticles for MRI of brain tumors. Curr. Pharm. Biotechnol. 13(12), 2403–2416 (2012).
Medline CASGoogle Scholar
36. Wu Y, Lu Z, Li Y, Yang J, Zhang X. Surface modification of iron oxide-based magnetic nanoparticles for cerebral theranostics: application and prospection. Nanomaterials 10(8), 1441 (2020).
Medline CASGoogle Scholar
37. Zhang L, Yu F, Cole AJ et al. Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J. 11(4), 693–699 (2009).
Medline CASGoogle Scholar
38. Chertok B, Moffat BA, David AE et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29(4), 487–496 (2008).
Medline CASGoogle Scholar
39. Kiessling F, Mertens ME, Grimm J, Lammers T. Nanoparticles for imaging: top or flop? Radiology 273(1), 10–28 (2014).
MedlineGoogle Scholar
40. Yang R, Fu C, Li N et al. Glycosaminoglycan-targeted iron oxide nanoparticles for magnetic resonance imaging of liver carcinoma. Mater. Sci. and Eng.: C Mater. Biol. Appl. 45, 556–563 (2014).
Medline CASGoogle Scholar
41. Liang J, Zhang X, Miao Y, Li J, Gan Y. Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma. Int. J. Nanomed. 12, 2033–2044 (2017).
Medline CASGoogle Scholar
42. Yan C, Wu Y, Feng J et al. Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. Int. J. Nanomed. 8, 245–255 (2013).
MedlineGoogle Scholar
43. Yang RM, Fu CP, Fang JZ et al. Hyaluronan-modified superparamagnetic iron oxide nanoparticles for bimodal breast cancer imaging and photothermal therapy. Int. J. Nanomed. 12, 197–206 (2017).
Medline CASGoogle Scholar
44. Li L, Wu C, Pan L et al. Bombesin-functionalized superparamagnetic iron oxide nanoparticles for dual-modality MR/NIRFI in mouse models of breast cancer. Int. J. Nanomed. 14, 6721–6732 (2019).
MedlineGoogle Scholar
45. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 49(3), 403–408 (2003).
Medline CASGoogle Scholar
46. Zou Q, Zhang CJ, Yan YZ, Min ZJ, Li CS. MUC-1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment. J. Cell. Biochem. 120(11), 18650–18658 (2019).
Medline CASGoogle Scholar
47. Wang L, Yin H, Bi R, Gao G, Li K, Liu HL. ENO1-targeted superparamagnetic iron oxide nanoparticles for detecting pancreatic cancer by magnetic resonance imaging. J. Cell. Mol. Med. 24(10), 5751–5757 (2020).
Medline CASGoogle Scholar
48. Ren S, Song L, Tian Y et al. Emodin-conjugated PEGylation of Fe₃O₄ nanoparticles for FI/MRI dual-modal imaging and therapy in pancreatic cancer. Int. J. Nanomed. 16, 7463–7478 (2021).
Medline CASGoogle Scholar
49. Luo Y, Li Y, Li J, Fu C, Yu X, Wu L. Hyaluronic acid-mediated multifunctional iron oxide-based MRI nanoprobes for dynamic monitoring of pancreatic cancer. RSC Adv. 9(19), 10486–10493 (2019).
Medline CASGoogle Scholar
50. Yari H, Gali H, Awasthi V. Nanoparticles for targeting of prostate cancer. Curr. Pharm. Des. 26(42), 5393–5413 (2020).
Medline CASGoogle Scholar
51. Tse BW, Cowin GJ, Soekmadji C et al. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine 10(3), 375–386 (2015).
CASGoogle Scholar
52. Zhu Y, Sun Y, Chen Y et al. In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int. J. Mol. Sci. 16(5), 9573–9587 (2015).
Medline CASGoogle Scholar
53. Ahmed M, Salam AB, Yates C et al. Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Int. J. Nanomed. 12, 6973–6984 (2017).
Medline CASGoogle Scholar
54. Vallabani N, Singh S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics. 3 Biotech 8(6), 279 (2018). • Summarizes the role of IONPs in various imaging modalities and for hyperthermia and photothermal therapy, enabling a clearer understanding of the advantages of IONPs and their development prospects.
MedlineGoogle Scholar
55. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9), 7442–7447 (2013).
Medline CASGoogle Scholar
56. El-Boubbou K. Magnetic iron oxide nanoparticles as drug carriers: clinical relevance. Nanomedicine 13(8), 953–971 (2018). •• Analyzes clinical progress in the use of IONPs and discusses current problems and aspects of active targeting that need to be addressed.
CASGoogle Scholar
57. Alexiou C, Arnold W, Hulin P et al. Therapeutic efficacy of ferrofluid bound anticancer agent. Magnetohydrodynamics 37(3), 318–322 (2001).
Google Scholar
58. Bañobre-López M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep. Pract. Oncol. Radiother. 18(6), 397–400 (2013).
MedlineGoogle Scholar
59. Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv. Drug Deliv. Rev. 63(9), 789–808 (2011).
Medline CASGoogle Scholar
60. Chatterjee DK, Diagaradjane P, Krishnan S. Nanoparticle-mediated hyperthermia in cancer therapy. Ther. Deliv. 2(8), 1001–1014 (2011).
Medline CASGoogle Scholar
61. Yoo D, Jeong H, Noh S, Lee J, Cheon J. Magnetically triggered dual functional nanoparticles for resistance-free apoptotic hyperthermia. Angew. Chem. Int. Ed. 52(49), 13047–13051 (2013).
Medline CASGoogle Scholar
62. Obaidat IM, Issa B, Haik Y. Magnetic properties of magnetic nanoparticles for efficient hyperthermia. Nanomaterials (Basel) 5(1), 63–89 (2015).
MedlineGoogle Scholar
63. Hayashi K, Nakamura M, Sakamoto W et al. Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics 3(6), 366–376 (2013).
Medline CASGoogle Scholar
64. Johannsen M, Gneveckow U, Taymoorian K et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int. J. Hyperthermia 23(3), 315–323 (2007).
Medline CASGoogle Scholar
65. Revia RA, Zhang M. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances. Mater. Today 19(3), 157–168 (2016).
Medline CASGoogle Scholar
66. Hu Y, Mignani S, Majoral JP, Shen M, Shi X. Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy. Chem. Soc. Rev. 47(5), 1874–1900 (2018).
Medline CASGoogle Scholar
67. Shen S, Tang H, Zhang X et al. Targeting mesoporous silica-encapsulated gold nanorods for chemo-photothermal therapy with near-infrared radiation. Biomaterials 34(12), 3150–3158 (2013).
Medline CASGoogle Scholar
68. Bagley AF, Hill S, Rogers GS, Bhatia SN. Plasmonic photothermal heating of intraperitoneal tumors through the use of an implanted near-infrared source. ACS Nano 7(9), 8089–8097 (2013).
Medline CASGoogle Scholar
69. Zhou Z, Sun Y, Shen J et al. Iron/iron oxide core/shell nanoparticles for magnetic targeting MRI and near-infrared photothermal therapy. Biomaterials 35(26), 7470–7478 (2014).
Medline CASGoogle Scholar
70. Chu M, Shao Y, Peng J et al. Near-infrared laser light mediated cancer therapy by photothermal effect of Fe₃O₄magnetic nanoparticles. Biomaterials 34(16), 4078–4088 (2013).
Medline CASGoogle Scholar
71. Shen S, Wang S, Zheng R et al. Magnetic nanoparticle clusters for photothermal therapy with near-infrared irradiation. Biomaterials 39, 67–74 (2015).
Medline CASGoogle Scholar
72. Feng L, Yang D, He F et al. A core-shell-satellite structured Fe₃O₄@g-C₃N₄-UCNPs-PEG for T₁/T₂-weighted dual-modal MRI-guided photodynamic therapy. Adv. Healthcare Mater. 6(18), 1700502 (2017).
Google Scholar
73. Li Z, Wang C, Cheng L et al. PG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted, NIR light induced, photodynamic therapy. Biomaterials 34(36), 9160–9170 (2013).
Medline CASGoogle Scholar
74. Shi J, Yu X, Wang L et al. PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging. Biomaterials 34(37), 9666–9677 (2013).
Medline CASGoogle Scholar
75. Canese R, Vurro F, Marzola P. Iron oxide nanoparticles as theranostic agents in cancer immunotherapy. Nanomaterials (Basel) 11(8), 1950 (2021).
Medline CASGoogle Scholar
76. Dadfar SM, Roemhild K, Drude NI et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 138, 302–325 (2019). •• Clear summary of the IONPs currently approved or in clinical trials and of key studies for in vitro and in vivo biomedical applications.
Medline CASGoogle Scholar
77. Denardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19(6), 369–382 (2019).
Medline CASGoogle Scholar
78. Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020). • Clearly explains the two subtypes of tumor-associated macrophages (TAMs) and their plasticity in response to changes in the tumor microenvironment or therapeutic intervention; summarizes the challenges in inhibiting the protumor effects of TAMs and discusses the potential use of TAMs as a therapeutic target.
Medline CASGoogle Scholar
79. Reichel D, Tripathi M, Perez JM. Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment. Nanotheranostics 3(1), 66–88 (2019).
MedlineGoogle Scholar
80. Corna G, Campana L, Pignatti E et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95(11), 1814–1822 (2010).
Medline CASGoogle Scholar
81. Wu X, Zhang H. Therapeutic strategies of iron–based nanomaterials for cancer therapy. Biomed. Mater. 16(3), 32003 (2021).
Medline CASGoogle Scholar
82. Zanganeh S, Hutter G, Spitler R et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11(11), 986–994 (2016).
Medline CASGoogle Scholar
83. Schwerdt JI, Goya GF, Calatayud MP, Hereñú CB, Reggiani PC, Goya RG. Magnetic field-assisted gene delivery: achievements and therapeutic potential. Curr. Gene Ther. 12(2), 116–126 (2012).
Medline CASGoogle Scholar
84. Wang X, Zhou Z, Wang Z et al. Gadolinium embedded iron oxide nanoclusters as T1–T2 dual-modal MRI-visible vectors for safe and efficient siRNA delivery. Nanoscale 5(17), 8098–8104 (2013).
Medline CASGoogle Scholar
85. Miao L, Zhang K, Qiao C et al. Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle-mediated gene expression. Nanomedicine 9(1), 141–150 (2013).
Medline CASGoogle Scholar
86. Jia N, Wu H, Duan J et al. Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for the delivery of small interfering RNA to macrophages in vitro and in vivo. J. Vis. Exp. (144), e58660 (2019).
Google Scholar
87. Baghban R, Afarid M, Soleymani J, Rahimi M. Were magnetic materials useful in cancer therapy? Biomed. Pharmacother. 144, 112321 (2021).
Medline CASGoogle Scholar
88. Dulińska-Litewka J, Bazarczyk A, Hałubiec P, Szafrański O, Karnas K, Karewicz A. Superparamagnetic iron oxide nanoparticles-current and prospective medical applications. Materials (Basel) 12(4), (2019).
MedlineGoogle Scholar

Vol. 17, No. 21

Metrics

Downloaded 156 times

History

Received 27 September 2022

Accepted 11 November 2022

Published online 2 December 2022

Published in print September 2022

Information

Keywords

Author contributions

C Wang and Y Li contributed equally to this work.

Financial & competing interests disclosure

This work was supported by the National Science Foundation of China (Grant No. 82060317). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download